Denali Therapeutics, Inc. (DNLI)
19.25
-1.16
(-5.68%)
USD |
NASDAQ |
May 07, 13:22
Denali Therapeutics SG&A Expense (TTM) : 136.56M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Biogen, Inc. | 2.468B |
| Neurocrine Biosciences, Inc. | 879.70M |
| Protalix Biotherapeutics, Inc. | 11.68M |
| Arcturus Therapeutics Holdings, Inc. | 46.08M |
| Agenus, Inc. | 54.39M |